Antibiotic
Journey Medical’s Emrosi Receives FDA Approval, Setting New Standard for Rosacea Treatment
Rosacea treatment, Emrosi, FDA approval, Minocycline hydrochloride, Journey Medical Corporation, Dermatological conditions, New standard of care
Iterum Therapeutics Secures FDA Approval for Orlynvah, Breaking Two-Decade Drought in New UTI Treatments
Iterum Therapeutics, FDA Approval, Orlynvah, Uncomplicated Urinary Tract Infections (uUTIs), Sulopenem Etzadroxil and Probenecid, Oral Penem
NICE Rejects Alzheimer’s Drug Kisunla Despite UK Regulatory Approval
NICE, Alzheimer’s disease, donanemab, Kisunla, Eli Lilly, MHRA, NHS, cost-effectiveness
Basilea Secures $268M BARDA Funding for Antifungal and Antibacterial Development
Basilea, BARDA, antifungals, antibacterials, biotech funding, pharmaceutical development
Crestone’s CRS3123 Shows Superior Efficacy in Curing C. difficile Infections and Preventing Recurrence Compared to Vancomycin in Phase 2 Trial
C. difficile infections, CRS3123, Vancomycin, Phase 2 clinical trial, Antibiotic efficacy, Recurrence prevention
FDA Raises Concerns Over Inappropriate Use of Iterum’s Antibiotic Ahead of Advisory Committee Meeting
Iterum Therapeutics, FDA, antibiotic resistance, sulopenem etzadroxil/probenecid, uncomplicated urinary tract infections (uUTIs), advisory committee meeting
UK Approves Leqembi for Alzheimer’s, but NICE Deems It Too Costly for NHS Use
Leqembi, Alzheimer’s disease, NICE, NHS, cost-effectiveness, UK approval
Leqembi, Biogen and Eisai’s Alzheimer’s Drug, Gains UK Approval but Faces Cost-Effectiveness Hurdle
Leqembi, Alzheimer’s disease, UK approval, NICE, cost-effectiveness, Biogen, Eisai
England’s NICE Approves Theramex’s Uterine Fibroids Treatment
NICE, Theramex, uterine fibroids, linzagolix, Yselty, GnRH antagonist, hormonal add-back therapy, NHS, women’s health
NICE Rejects AstraZeneca’s Enhertu for Breast Cancer Treatment Due to Pricing Concerns
NICE, AstraZeneca, Enhertu, Breast Cancer, Pricing, Rejection